SCHEMBL12266264

SCHEMBL12266264

NCCOB(c1ccc(C(F)(F)F)cc1)c1c2ccccc2c(B(OCCN)c2ccc(C(F)(F)F)cc2)c2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.51
▸ TSHR P16473 2/20 0.51
▸ KDM4E B2RXH2 1/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ TRPM2 O94759 1/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ THRB P10828 1/20 0.51
▸ HPGD P15428 1/20 0.51
▸ ALOX15 P16050 1/20 0.51
▸ ALOX12 P18054 1/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ TDP1 Q9NUW8 1/20 0.51
▸ TRPV6 Q9H1D0 2/20 0.39
▸ TAAR1 Q96RJ0 1/20 0.38
▸ SLC6A4 P31645 3/20 0.37
▸ SLC6A2 P23975 2/20 0.37
▸ SLC6A3 Q01959 2/20 0.37
▸ KCNK2 O95069 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12270971 0.90 CYP1A2 (0.42) ALDH1A1TSHRKDM4EMEN1TRPM2
SCHEMBL13476030 0.88 MEN1 (0.40) ALDH1A1TSHRKDM4EMEN1TRPM2
SCHEMBL12319389 0.86 CYP1A2 (0.58) ALDH1A1TSHRKDM4EMEN1TRPM2
SCHEMBL12270665 0.79 CYP1A2 (0.50) ALDH1A1TSHRKDM4EMEN1TRPM2
SCHEMBL12266259 0.73 MAOB (0.62) ALDH1A1TSHRKDM4EMEN1TRPM2
SCHEMBL2412888 0.71 KDM4E (0.96) ALDH1A1TSHRKDM4EMEN1TRPM2
SCHEMBL14198827 0.71 KDM4E (0.79) ALDH1A1TSHRKDM4EMEN1TRPM2
SCHEMBL3279116 0.71 TRPV6 (0.50) ALDH1A1TSHRKDM4EMEN1TRPM2
SCHEMBL4169832 0.70 KDM4E (0.64) ALDH1A1TSHRKDM4EMEN1TRPM2
SCHEMBL341835 0.69 KDM4E (1.00) ALDH1A1TSHRKDM4EMEN1TRPM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853424-B2 Protein cross-linking inhibitor JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2014-10-07 — — US disclosed
US-8017809-B2 Bisboron compound JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2011-09-13 — — US disclosed
US-20110212919-A1 PROTEIN CROSS-LINKING INHIBITOR JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2011-09-01 — — US disclosed
US-20100087645-A1 NOVEL BISBORON COMPOUND JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2010-04-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212919-A1 PROTEIN CROSS-LINKING INHIBITOR BAZ2B, PRMT1, BRIX1 ALDH1A1 4540/4885TSHR 2155/4885KDM4E 1022/4885
US-20100087645-A1 NOVEL BISBORON COMPOUND KCNMB4, CA2, NR0B2 ALDH1A1 4802/4885TSHR 977/4885KDM4E 3037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback